Figure 2
Kaplan-Meier product-limit estimates / 5-y event-free survival: (A) ≥
70% reduction in AFP levels (81.3%) vs. < 70% reduction
(40%), P=0.02, (B) Time from HB diagnosis to LDLT, t> 12 mo. (40%) vs. t < 12 mo (77%),
P=0.01, (C) PLADO Qtx regimen (76.9%) vs. other Qtx regimens (50%),
P=0.14, (D) primary LDLT (67.7%) vs. rescue LT (33.3%), P=0.04.